AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 phase I trial

被引：4
|
作者：
Strickler, J. H. [1 ]
Fakih, M. [2 ]
Price, T. J. [3 ]
Desai, J. [4 ]
Durm, G. [5 ]
Krauss, J. C. [6 ]
Kuboki, Y. [7 ]
Kim, T. W. [8 ]
Sacher, A. [9 ]
Henary, H. [10 ]
Kim, J. [11 ]
Hong, D. S. [12 ]
机构：
[1] Duke Canc Ctr, Med, Durham, NC USA
[2] City Hope Natl Med Ctr, Med Oncol & Therapeut Res, Duarte, CA USA
[3] Queen Elizabeth Hosp, Emergency Dept, Med Oncol, Woodville, SA, Australia
[4] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
[5] Dept Med, Div Hematol Oncol, Indianapolis, IN USA
[6] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI 48109 USA
[7] Canc Inst Hosp JFCR, Dept Expt Therapeut & GI Oncol, Tokyo, Japan
[8] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[9] Princess Margaret Canc Ctr, Med Oncol & Hematol Dept, Toronto, ON, Canada
[10] Amgen Inc, Early Dev Oncol Dept, Thousand Oaks, CA USA
[11] Amgen Inc, Biostat, Thousand Oaks, CA USA
[12] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeuitcs Dept, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.103
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
83MO
引用
收藏
页码：S1274 / S1275
页数：2
相关论文
共 34 条
  • [31] A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy
    Ramanathan, Ramesh K.
    Stephenson, Joe J.
    Weiss, Glen J.
    Pestano, Linda A.
    Lowe, Ann
    Hiscox, Alton
    Leos, Rafael A.
    Martin, Julie C.
    Kirkpatrick, Lynn
    Richards, Donald A.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1591 - 1596
  • [32] Clinicogenomic real-world data analysis of patients (pts) with KRAS G12C-mutant advanced non-small cell lung cancer (aNSCLC) from the natural history cohort of the Blood First Assay Screening Trial (BFAST).
    Dziadziuszko, Rafal
    Li, Xiao
    Anderson, Eric C.
    Zer, Alona
    Corrales-Rodriguez, Luis
    Cheema, Parneet
    Szczesna, Aleksandra
    Philco, Manuel
    Mathisen, Michael
    Paul, Sarah M.
    Bhagawati-Prasad, Vijay
    Pathria, Gaurav
    Shi, Zhen
    Hilton, Magalie
    Zhang, Qing
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Preliminary results from ERAS-007 plus palbociclib (palbo) in patients (pts) with KRAS/NRAS mutant (m) colorectal cancer (CRC) or KRASm pancreatic ductal adenocarcinoma (PDAC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers)
    Ulahannan, Susanna Varkey
    Spigel, David R.
    Lee, Michael Sangmin
    Fakih, Marwan
    Grierson, Patrick
    Christenson, Eric
    Chiorean, E. Gabriela
    Alan, Darryl
    Khan, Outlaw Gazala
    Atreya, Chloe Evelyn
    Parikh, Aparna Raj
    Dayyani, Farshid
    Spira, Alexander I.
    Kopetz, Scott
    Bullock, Andrea J.
    Li, Zhengrong
    Chen, Xiaoying
    Patel, Hina
    Hazra, Saswati
    Strickler, John H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.
    Tolcher, Anthony W.
    Reeves, James Andrew
    McKean, Meredith
    Chmielowski, Bartosz
    Beck, Joseph Thaddeus
    Shaheen, Montaser F.
    Somaiah, Neeta
    Wilson, Melissa
    Spira, Alexander I.
    Drabick, Joseph J.
    Tang, Yuefen
    Winkler, Robert
    Li, Mingyu
    Ahmad, Mohammad
    Lu, Ming
    Liang, Zhiyan
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
1234